The regulatory landscape for compounded peptides may be poised for a significant shift.

On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee ("PCAC") voted in favor of allowing four widely discussed peptides—BPC-157, KPV, TB-500, and MOTS-C—to move forward toward potential inclusion on the list of bulk drug substances that may be used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The votes are particularly notable because the Committee reached its recommendations despite concerns raised by FDA scientists regarding the limited clinical evidence and potential safety risks associated with the substances. The development could have significant implications for compounding pharmacies, telehealth platforms, medical practices, wellness providers, and other businesses operating in the rapidly expanding peptide market.

The Committee’s votes do not mean that these peptides are now FDA-approved drugs. Nor do the votes immediately authorize unrestricted compounding, prescribing, marketing, or sale of the products. PCAC is an advisory committee. Its recommendations are nonbinding, and the FDA must determine what regulatory action to take next. Accordingly, a favorable PCAC vote should be understood as an important regulatory development, but not as an FDA finding that a peptide is safe and effective for a particular medical use.

If you need guidance or clarification on this or any other healthcare legal issue, you may reach our experienced healthcare attorneys at MDRXLaw via email at info@mdrxlaw.comor by phone or text at 212.668.0200.